111 Capital Sells 6,970 Shares of Hims & Hers Health, Inc. $HIMS

111 Capital lessened its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 32.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,481 shares of the company’s stock after selling 6,970 shares during the quarter. 111 Capital’s holdings in Hims & Hers Health were worth $722,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in HIMS. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health in the 1st quarter worth about $30,000. UMB Bank n.a. increased its stake in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after buying an additional 933 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Hims & Hers Health in the 1st quarter worth about $41,000. Larson Financial Group LLC increased its stake in Hims & Hers Health by 47.7% in the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after buying an additional 458 shares during the period. Finally, Webster Bank N. A. increased its stake in Hims & Hers Health by 229.1% in the 2nd quarter. Webster Bank N. A. now owns 905 shares of the company’s stock worth $45,000 after buying an additional 630 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Zacks Research downgraded shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. UBS Group set a $30.00 target price on shares of Hims & Hers Health in a research report on Monday, June 23rd. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Canaccord Genuity Group reissued a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a research report on Friday, September 12th. Finally, Wall Street Zen downgraded shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Two equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $38.92.

Hims & Hers Health Stock Down 9.1%

Shares of Hims & Hers Health stock opened at $52.61 on Friday. The firm’s 50 day moving average price is $51.47 and its 200-day moving average price is $47.25. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 52-week low of $16.69 and a 52-week high of $72.98. The company has a market cap of $11.89 billion, a P/E ratio of 65.77, a PEG ratio of 3.55 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. During the same period in the previous year, the firm earned $0.06 EPS. The firm’s quarterly revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the transaction, the insider owned 169,940 shares of the company’s stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the completion of the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at approximately $7,139,264.40. The trade was a 52.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,622,727 shares of company stock valued at $83,566,691 in the last 90 days. Insiders own 13.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.